397 related articles for article (PubMed ID: 24744580)
1. Treatment options in patients with metastatic gastric cancer: current status and future perspectives.
Bilici A
World J Gastroenterol; 2014 Apr; 20(14):3905-15. PubMed ID: 24744580
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A
Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651
[TBL] [Abstract][Full Text] [Related]
3. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
Thuss-Patience PC; Shah MA; Ohtsu A; Van Cutsem E; Ajani JA; Castro H; Mansoor W; Chung HC; Bodoky G; Shitara K; Phillips GDL; van der Horst T; Harle-Yge ML; Althaus BL; Kang YK
Lancet Oncol; 2017 May; 18(5):640-653. PubMed ID: 28343975
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy for advanced gastric cancer.
Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer.
Mondaca S; Margolis M; Sanchez-Vega F; Jonsson P; Riches JC; Ku GY; Hechtman JF; Tuvy Y; Berger MF; Shah MA; Kelsen DP; Ilson DH; Yu K; Goldberg Z; Epstein AS; Desai A; Chung V; Chou JF; Capanu M; Solit DB; Schultz N; Janjigian YY
Gastric Cancer; 2019 Mar; 22(2):355-362. PubMed ID: 30088161
[TBL] [Abstract][Full Text] [Related]
7. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.
Tabernero J; Hoff PM; Shen L; Ohtsu A; Shah MA; Cheng K; Song C; Wu H; Eng-Wong J; Kim K; Kang YK
Lancet Oncol; 2018 Oct; 19(10):1372-1384. PubMed ID: 30217672
[TBL] [Abstract][Full Text] [Related]
8. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.
Bang YJ
J Clin Gastroenterol; 2012 Sep; 46(8):637-48. PubMed ID: 22751336
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Bang YJ; Van Cutsem E; Feyereislova A; Chung HC; Shen L; Sawaki A; Lordick F; Ohtsu A; Omuro Y; Satoh T; Aprile G; Kulikov E; Hill J; Lehle M; Rüschoff J; Kang YK;
Lancet; 2010 Aug; 376(9742):687-97. PubMed ID: 20728210
[TBL] [Abstract][Full Text] [Related]
10. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
Tintelnot J; Goekkurt E; Binder M; Thuss-Patience P; Lorenzen S; Knorrenschild JR; Kretzschmar A; Ettrich T; Lindig U; Jacobasch L; Pink D; Al-Batran SE; Hinke A; Hegewisch-Becker S; Nilsson S; Bokemeyer C; Stein A
BMC Cancer; 2020 Jun; 20(1):503. PubMed ID: 32487035
[TBL] [Abstract][Full Text] [Related]
11. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
Janjigian YY; Maron SB; Chatila WK; Millang B; Chavan SS; Alterman C; Chou JF; Segal MF; Simmons MZ; Momtaz P; Shcherba M; Ku GY; Zervoudakis A; Won ES; Kelsen DP; Ilson DH; Nagy RJ; Lanman RB; Ptashkin RN; Donoghue MTA; Capanu M; Taylor BS; Solit DB; Schultz N; Hechtman JF
Lancet Oncol; 2020 Jun; 21(6):821-831. PubMed ID: 32437664
[TBL] [Abstract][Full Text] [Related]
12. A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.
Gomez-Martín C; Lopez-Rios F; Aparicio J; Barriuso J; García-Carbonero R; Pazo R; Rivera F; Salgado M; Salud A; Vázquez-Sequeiros E; Lordick F
Cancer Lett; 2014 Aug; 351(1):30-40. PubMed ID: 24943493
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
[TBL] [Abstract][Full Text] [Related]
14. Combination of trastuzumab and triple FLOT chemotherapy (5-fluorouracil/leucovorin, oxaliplatin, and docetaxel) in patients with HER2-positive metastatic gastric cancer: report of 3 cases.
Al-Batran SE; Hozaeel W; Jäger E
Onkologie; 2012; 35(9):505-8. PubMed ID: 23007148
[TBL] [Abstract][Full Text] [Related]
15. Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Al-Batran SE; Moorahrend E; Maintz C; Goetze TO; Hempel D; Thuss-Patience P; Gaillard VE; Hegewisch-Becker S
Oncologist; 2020 Aug; 25(8):e1181-e1187. PubMed ID: 32311799
[TBL] [Abstract][Full Text] [Related]
16. Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer.
Palacio S; Loaiza-Bonilla A; Kittaneh M; Kyriakopoulos C; Ochoa RE; Escobar M; Arango B; Restrepo MH; Merchan JR; Rocha Lima CM; Hosein PJ
Anticancer Res; 2014 Jan; 34(1):301-6. PubMed ID: 24403478
[TBL] [Abstract][Full Text] [Related]
17. [HER2 and gastric cancer: a novel therapeutic target for trastuzumab].
Bouché O; Penault-Llorca F
Bull Cancer; 2010 Dec; 97(12):1429-40. PubMed ID: 21134821
[TBL] [Abstract][Full Text] [Related]
18. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y; Moldovan M; Chang Lee R; Hsieh AH; Townsend A; Price T
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD012078. PubMed ID: 33210731
[TBL] [Abstract][Full Text] [Related]
19. [Progress in chemotherapy for advanced gastric cancer].
Xu RH; Teng KY
Ai Zheng; 2009 Oct; 28(10):1108-13. PubMed ID: 19799823
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group.
Hofheinz RD; Hegewisch-Becker S; Kunzmann V; Thuss-Patience P; Fuchs M; Homann N; Graeven U; Schulte N; Merx K; Pohl M; Held S; Keller R; Tannapfel A; Al-Batran SE
Int J Cancer; 2021 Sep; 149(6):1322-1331. PubMed ID: 34019698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
